Olema Pharmaceuticals (OLMA) Cash from Investing Activities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash from Investing Activities data on file, last reported at $4.5 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $4.5 million, up 110.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$106.1 million (up 10.4% YoY), and the FY2025 annual result was -$155.8 million, down 66.54% from the prior year.
• Cash from Investing Activities improved to $4.5 million in Q1 2026 per OLMA's latest filing, from -$162.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $45.9 million in Q3 2024 and troughed at -$162.2 million in Q4 2025.
• A 5-year average of -$9.3 million and a median of $14.1 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities tumbled 289.24% in 2023, then jumped 801.8% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $16.3 million in 2022, then plunged by 289.24% to -$30.9 million in 2023, then plunged by 270.12% to -$114.4 million in 2024, then tumbled by 41.74% to -$162.2 million in 2025, then surged by 102.79% to $4.5 million in 2026.
• Business Quant data shows OLMA's Cash from Investing Activities at $4.5 million in Q1 2026, -$162.2 million in Q4 2025, and $17.3 million in Q3 2025.